Human CYP3A4-introduced HepG2 cells: In vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity

Xenobiotica

Volumn 38, Issue 11, 2008, Pages 1355-1364

  Araki, N ^a   Tsuruoka, S ^a,e   Wang, N ^a,b   Hasegawa, G ^a   Yanagihara, H ^a   Ando, H ^a   Omasa, T ^c   Enosawa, S ^d   Nagai, H ^a   Fujimura, A ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c OSAKA UNIVERSITY   (Japan)

^d NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

CYP3A4; Drug interaction; HepG2; Screening

Indexed keywords

AMMONIA; ATORVASTATIN; CIMETIDINE; CYTOCHROME P450 3A4; DIAZEPAM; FLUVOXAMINE; KETOCONAZOLE; LIDOCAINE; NIFEDIPINE; NORDAZEPAM; OMEPRAZOLE; OXAZEPAM; OXIDOREDUCTASE; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; TEMAZEPAM;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; WESTERN BLOTTING;

AMMONIA; ANIMALS; CELL LINE, TUMOR; CRICETINAE; CYTOCHROME P-450 CYP3A; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GLUTAMATE-AMMONIA LIGASE; HEPTANOIC ACIDS; HUMANS; KETOCONAZOLE; LIDOCAINE; NIFEDIPINE; PYRROLES;

EID: 55549115339     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802468645     Document Type: Article

References (19)

1. Azzam R, Notarianni L, Ali H. 1998. Rapid and simple chromatographic method for the determination of diazepam and its major metabolites in human plasma and urine. Journal of Chromatography B: Biomedical Science Applications 708:304-309.
2. Bargetzi M, Aoyama T, Gonzalez F, Meyer U. 1989. Lidocaine metabolism in human liver microsome by cytochrome P450IIIA4. Clinical Pharmacology and Therapeutics 46:521-527.
3. Chen Y, Potter J, Ravenscroft J. 1992. A quick, sensitive high-performance liquid chromatography assay for monoethylglycinexylidide and lignocaine in serum/plasma using solid-phase extraction. Therapeutic Drug Monitoring 14:317-322.
4. Edwards I. 1997. Pharmacological basis of adverse drug reactions. In: Speight T, Holford N, editors. Avery's drug treatment. Auckland: Adis International. pp 261-299.
5. Hindriks F, Groen A. 1978. Evaluation of the enzymatic ammonia method for urine on the Du Pont automatic clinical analyzer. Journal of Clinical Chemistry and Clinical Biochemistry 16:289-291.
6. Jemal M, Ouyang Z, Chen B, Teitz D. 1999. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Communications in Mass Spectrometry 13:1003-1015.
7. Maezono S, Sugimoto K, Sakamoto K, Ohmori M, Hishikawa S, Mizuta K, Kawarasaki H, Watanabe Y, Fujimura A. 2005. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: Involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatric Transplantation 9:315-323.
8. Niwa T, Shiragi T, Yamasaki S, Ishibashi K, Ohno Y, Kagayama A. 2003. In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsome. Xenobiotica 33:717-729.
9. Omasa T, Kim K, Hiramatsu S, Katakura Y, Kishimoto M, Enosawa S, Ohtake H. 2005. Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system. Biotechnology Progress 21:161-167.
10. Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez F, Satoh T. 1996. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 26:1155-1166.
11. Polasek T, Miners J. 2007. In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opinions in Drug Metabolism and Toxicology 3:321-329.
12. Quinn D, Day R. 1997. Clinically important drug interactions. In: Speight T, Holford N, editors. Avery's drug treatment. Auckland: Adis International. pp 302-337.
13. Rawden H, Carlile D, Tindal A, Hallifax D, Galetin A, Ito K, Houston J. 2005. Microsomal prediction of in vitro clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica 35:603-625.
14. Spilker B. 1997. Drug development and approval processes. In: Speight T, Holford N, editors. Avery's drug treatment. Auckland: Adis International. pp 423-450.
15. Strobel H, Dignam D. 1978. Purification and properties of NADPH-cytochrome P450 reductase. In: Fleischer S, Packer L, editors. Methods in enzymology. New York, NY: Academic Press. pp 88-96.
16. Tang W, Wang R, Lu A. 2005. Utility of recombinant cytochrome p450 enzymes: A drug metabolism perspective. Current Drug Metabolism 6:503-517.
17. Wang N, Tsuruoka S, Yamamoto H, Enosawa S, Omasa T, Sata N, Matsumura T, Nagai H, Fujimura A. 2005. The bioreactor with CYP3A4- and glutamine synthetase-introduced HepG2 cells: Treatment of hepatic failure dog with diazepam overdosage. Artificial Organs 29:681-684.
18. Yun C, Yim S, Kim D, Ahn T. 2006. Functional expression of human cytochrome P450 enzymes in Escherichia coli. Current Drug Metabolism 7:411-429.
19. Zhou SF. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism 9:310-322.